ArticlePaediatrics & child health2025
Home-based phototherapy for neonatal hyperbilirubinemia: A one-time Canadian Paediatric Surveillance Program Survey.
Article in Paediatrics & child health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Home-based phototherapy (HP) has gained traction as an alternative to hospital-based treatment for neonatal hyperbilirubinemia, but the safety of this practice remains unclear. This study aimed to identify adverse events (AEs) associated with HP in Canada. Methods: A one-time survey, distributed through the Canadian Paediatric Surveillance Program, collected retrospective data from paediatricians. The survey included questions about the use of HP, AEs associated with HP, potential HP AE risk factors, and outcomes. A descriptive statistical analysis was conducted. Results: The survey response rate was 31% (844/2741), with 497 respondents indicating that they provide care for neonatal hyperbilirubinemia. Among those 497 respondents, 58 (12%) reported working at a centre that provides HP. AEs were reported by 15 (3%) physicians with 21 cases of AEs associated with HP in the preceding 12 months. Most AEs resulted in admissions or readmissions to the hospital for inpatient phototherapy. No serious AEs or long-term consequences were reported. Risk factors were identified in 67% of cases, with infant-related factors identified more frequently than provider, system, or family-related factors. Formal protocols for patient assessment and follow-up were in place at most centres that provide HP. Conclusion: This survey revealed no serious AEs related to HP, as reported by paediatricians in Canada, in the preceding 12 months. The survey also revealed that while HP is available in Canada, there is limited access and a lack of standardization to its administration. This study provides valuable insights into the safety and practice of HP for neonatal hyperbilirubinemia in Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.